EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Bovine colostrum as a fortifier to human milk in very preterm infants – A randomized controlled trial (FortiColos)

Agnethe May Ahnfeldt, Lise Aunsholt, Bo Moelholm Hansen, Bente Hoest, Valdís Jóhannsdóttir, Susanne Soendergaard Kappel, Anja Klamer, Sören Möller, Bertha Kanijo Moeller, Per Torp Sangild, Ann Lawaetz Skovgaard, Gerrit van Hall und 2 weitere

Clinical Nutrition · 2023

DOI: 10.1016/j.clnu.2023.03.008 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Nutrition, 2023. Verfasst von Agnethe May Ahnfeldt und 13 weiteren Autor:innen. Beteiligte Einrichtung: Section of Comparative Pediatrics and Nutrition, University of Copenhagen, Frederiksberg, Denmark. Hauptthemen laut MEDLINE: Sepsis, Infant, Premature, Diseases, Enterocolitis, Necrotizing. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovationsfonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Human milk for very preterm infants need fortification for optimal growth and development but the optimal fortification product remains to be identified. AIMS: To investigate feasibility, safety and preliminary efficacy on growth and blood biochemistry when using intact bovine colostrum (BC) as a fortifier to human milk in very preterm infants. METHODS: In an open-label, multicenter, randomized controlled pilot trial (infants 26-31 weeks' gestation), mother's own milk or donor human milk was fortified with powdered BC (n = 115) or a conventional fortifier (CF, bovine-milk-based, n = 117) until 35 weeks' postmenstrual age. Fortifiers and additional micronutrients were added to human milk according to local guidelines to achieve optimal growth (additional protein up to +1.4 g protein/100 mL human milk). Anthropometry was recorded weekly. Clinical morbidities including necrotizing enterocolitis (NEC) and late-onset sepsis (LOS) were recorded. Clinical biochemistry included plasma amino acid (AA) levels to assess protein metabolic responses to the new fortifier. RESULTS: A total of 232 infants, gestational age (GA) 28.5 ± 1.4 (weeks + days), fulfilled inclusion criteria. Birthweight, GA and delta Z scores from birth to end of intervention on weight, length or head circumference did not differ between groups, nor between the subgroups of small for gestational age infants. Likewise, incidence of NEC (BC: 3/115 vs. CF: 5/117, p = 0.72, unadjusted values), LOS (BC: 23/113 vs. CF: 14/116, p = 0.08) and other morbidities did not differ. BC infants received more protein than CF infants (+10%, p < 0.05) and showed several elevated AA levels (+10-40%, p < 0.05). CONCLUSION: Infants fortified with BC showed similar growth but received more protein and showed a moderate increase in plasma AA-levels, compared with CF. Adjustments in protein composition and micronutrients in BC-based fortifiers may be required to fully suit the needs for very preterm infants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SepsisInfant, Premature, DiseasesEnterocolitis, NecrotizingInfantPregnancyFemaleInfant, NewbornAnimalsCattleHumansMilk, HumanInfant, PrematureColostrumInfant, Very Low Birth WeightMicronutrientsFood, Fortified

Stichwörter der Autor:innen

Amino acid metabolismFortificationGrowthHuman milkPrematurity

Substanzen

Micronutrients

Autor:innen und Institutionen

  • Section of Comparative Pediatrics and Nutrition, University of Copenhagen, Frederiksberg, Denmark.
  • Section of Comparative Pediatrics and Nutrition, University of Copenhagen, Frederiksberg, Denmark; Department of Neonatology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
  • Department of Pediatrics, Copenhagen University Hospital North Zealand, Hilleroed, Denmark.
  • Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark.
  • Hans Christian Andersen Children's Hospital, Odense University Hospital, Odense, Denmark.
  • Department of Pediatrics, Hospital Lillebaelt, Kolding, Denmark.

Förderung

  • Innovationsfonden

Zitieren

APA

Ahnfeldt, A. M., Aunsholt, L., Hansen, B. M., Hoest, B., Jóhannsdóttir, V., Kappel, S. S., Klamer, A., Möller, S., Moeller, B. K., Sangild, P. T., Skovgaard, A. L., van Hall, G., Vibede, L. D., & Zachariassen, G. (2023). Bovine colostrum as a fortifier to human milk in very preterm infants – A randomized controlled trial (FortiColos). Clinical Nutrition. https://doi.org/10.1016/j.clnu.2023.03.008

Vancouver

Ahnfeldt AM, Aunsholt L, Hansen BM, Hoest B, Jóhannsdóttir V, Kappel SS, et al. Bovine colostrum as a fortifier to human milk in very preterm infants – A randomized controlled trial (FortiColos). Clinical Nutrition. 2023. doi:10.1016/j.clnu.2023.03.008

BibTeX
@article{Ahnfeldt2023,
  author = {Ahnfeldt, Agnethe May and Aunsholt, Lise and Hansen, Bo Moelholm and Hoest, Bente and Jóhannsdóttir, Valdís and Kappel, Susanne Soendergaard and Klamer, Anja and Möller, Sören and Moeller, Bertha Kanijo and Sangild, Per Torp and Skovgaard, Ann Lawaetz and van Hall, Gerrit and Vibede, Louise Dyrberg and Zachariassen, Gitte},
  title = {Bovine colostrum as a fortifier to human milk in very preterm infants – A randomized controlled trial (FortiColos)},
  journal = {Clinical Nutrition},
  year = {2023},
  doi = {10.1016/j.clnu.2023.03.008}
}
Kostenlos starten →